Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) shares fell -3.20% in last trading session and ended the day at $118.18. ANAC Gross Margin is 95.60% and its has a return on assets of -34.70%. Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) quarterly performance is -19.29%.
Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) announced top-line results from the long-term safety study of Crisaborole Topical Ointment, 2% (formerly AN2728), a novel non-steroidal topical anti-inflammatory phosphodiesterase-4 (PDE-4) inhibitor in development for the potential treatment of mild-to-moderate atopic dermatitis in children and adults.
China Petroleum & Chemical Corp. (NYSE:SNP) ended the last trading day at $73.04. Company weekly volatility is calculated as 1.94% and price to cash ratio as 8.18. China Petroleum & Chemical Corp. (NYSE:SNP) showed a weekly performance of -0.56%.
China Petroleum & Chemical Corp (ADR) (NYSE:SNP) also known as Sinopec Corp. has announced that it has completed expansion works in China’s eastern refinery. The expansion will allow Sinopec to refine an additional 100,000 barrels per day (bpd) crude oil. It also plans to increase its throughput in the fourth quarter of fiscal year 2015 (4QFY15). Located in eastern province of Jiangxi, the company’s Jiujiang refinery will be able to process 20% more crude oil in the coming quarter as a result of this expansion. The expansion was expected to be completed in September, however; the company’s internal issues including corruption scandal against the company’s top representatives also delayed the expansion process.
On 04 November, Wausau Paper Corp. (NYSE:WPP) shares decreased -0.10% and was closed at $10.17. WPP EPS growth in last 5 year was -23.20%. Wausau Paper Corp. (NYSE:WPP) year to date (YTD) performance is -9.71%.
Wausau Paper (NYSE:WPP) release 2015 third-quarter financial results on Thursday, November 5, prior to opening of the New York Stock Exchange. No analyst call will be held in conjunction with this earnings release. On Tuesday, October 13, in a joint announcement, the Company along with SCA Americas Inc., a division of Stockholm, Sweden, based Svenska Cellulosa Aktiebolaget SCA, entered into an agreement and plan of merger under which the Company will become a wholly-owned subsidiary of SCA Americas. The transaction, subject to customary regulatory and Company shareholder approvals, is anticipated to close during the first quarter of 2016.
Foundation Medicine, Inc. (NASDAQ:FMI) shares decreased -27.66% in last trading session and ended the day at $17.31. FMI Gross Margin is 56.60% and its has a return on assets of -46.00%. Foundation Medicine, Inc. (NASDAQ:FMI) quarterly performance is -13.45%.
Foundation Medicine, Inc. (NASDAQ: FMI) announced that F. Hoffmann La-Roche’s affiliate in Israel, Roche Pharmaceuticals (Israel) Ltd., will commence commercial activities in support of its suite of molecular information products. As part of the ex-US collaboration between Foundation Medicine and Roche, Roche Israel will act as the exclusive distributor of Foundation Medicine’s current products and services in Israel commencing as of October 24, 2015. The companies will also cooperate on the continued development of Foundation Medicine’s groundbreaking molecular information products to drive precision medicine and deliver improved clinical outcomes in cancer.
Medivation, Inc. (NASDAQ:MDVN) caters to the Healthcare space. It has a net profit margin of 34.00% and weekly performance is -1.77%. On the last day of trading company shares ended up at $44.97. Medivation, Inc. (NASDAQ:MDVN) distance from 50-day simple moving average (SMA50) is 3.51%.
Zacks cut shares of Medivation (NASDAQ:MDVN) from a strong-buy rating to a hold rating in a research note released on Wednesday morning.
Leave a Reply